Analyst Reco. Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Real-time Estimate Cboe BZX Other stock markets 03:48:45 2024-06-13 pm EDT			5-day change	1st Jan Change
17.93 ^USD	-1.48%		+6.87%	-35.95%

Jun. 04	Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses	CI
May. 09	Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating	May. 09	MT
Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating	Apr. 15	MT
JMP Securities Raises Pharvaris' Price Target to $49 From $40, Maintains Market Outperform Rating	Jan. 23	MT
Morgan Stanley Raises Price Target on Pharvaris to $35 From $32, Keeps Overweight Rating	Dec. 07	MT
Wedbush Raises Pharvaris' Price Target to $35 From $24, Outperform Rating Kept	Dec. 06	MT
Job losses delight investors	Dec. 06
Morgan Stanley Adjusts Price Target on Pharvaris to $32 From $34, Maintains Overweight Rating	Nov. 14	MT
Wedbush Lowers Pharvaris' PT to $24 From $27, Increases Share Count Assumptions Following Q3 Update, Keeps Outperform Rating Ahead of CHAPTER-1 Data	Nov. 03	MT
Wedbush Initiates Pharvaris at Outperform With $27 Price Target, Sees Opportunity for PHVS416 in the Acute HAE Therapeutic Setting	23-09-25	MT
Wedbush Initiates Pharvaris at Outpeform With $27 Price Target	23-09-25	MT
Morgan Stanley Upgrades Pharvaris to Overweight From Equalweight, Boosts Price Target to $34 From $10	23-08-15	MT
Oppenheimer Raises Pharvaris Price Target to $26 From $24, Maintains Outperform Rating	23-06-27	MT
JMP Securities Adjusts Pharvaris' Price Target to $20 From $23, Keeps Market Outperform Rating	23-04-06	MT
SVB Securities Adjusts Pharvaris' Price Target to $18 From $20, Keeps Outperform Rating	23-02-03	MT
JMP Securities Adjusts Pharvaris' Price Target to $23 From $22, Keeps Market Outperform Rating	23-01-11	MT
JMP Securities Adjusts Price Target on Pharvaris to $22 From $18, Maintains Market Outperform Rating	22-12-09	MT
Oppenheimer Adjusts Pharvaris Price Target to $24 From $22, Maintains Outperform Rating	22-12-09	MT
SVB Securities Adjusts Price Target on Pharvaris to $20 From $25, Keeps Outperform Rating	22-09-14	MT
Oppenheimer Adjusts Pharvaris Price Target to $22 From $48, Maintains Outperform Rating	22-08-23	MT
SVB Securities Adjusts Pharvaris' Price Target to $25 From $45, Maintains Outperform Rating	22-08-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Analyst Reco.

Filters